<SEC-DOCUMENT>0001193125-23-158451.txt : 20230602
<SEC-HEADER>0001193125-23-158451.hdr.sgml : 20230602
<ACCEPTANCE-DATETIME>20230601081651
ACCESSION NUMBER:		0001193125-23-158451
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230601
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230601
DATE AS OF CHANGE:		20230601

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEI Pharma, Inc.
		CENTRAL INDEX KEY:			0001262104
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				510407811
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50484
		FILM NUMBER:		23983058

	BUSINESS ADDRESS:	
		STREET 1:		11455 EL CAMINO REAL
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-369-7100

	MAIL ADDRESS:	
		STREET 1:		11455 EL CAMINO REAL
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARSHALL EDWARDS INC
		DATE OF NAME CHANGE:	20030902
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d438169d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:meip="http://www.meipharma.com/20230601" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-06-01_to_2023-06-01">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-06-01_to_2023-06-01">0001262104</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="meip-20230601.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-06-01_to_2023-06-01"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001262104</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-06-01</xbrli:startDate> <xbrli:endDate>2023-06-01</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-06-01_to_2023-06-01">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(D)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-06-01_to_2023-06-01" format="ixt:datemonthdayyearen">June 1, 2023</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of report (Date of earliest event reported)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-06-01_to_2023-06-01">MEI Pharma, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-06-01_to_2023-06-01" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-06-01_to_2023-06-01">000-50484</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-06-01_to_2023-06-01">51-0407811</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-06-01_to_2023-06-01">11455 El Camino Real</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-06-01_to_2023-06-01">Suite 250</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-06-01_to_2023-06-01">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-06-01_to_2023-06-01" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-06-01_to_2023-06-01">92130</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-06-01_to_2023-06-01">(858)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-06-01_to_2023-06-01">369-7100</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-06-01_to_2023-06-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-06-01_to_2023-06-01" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-06-01_to_2023-06-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-06-01_to_2023-06-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of Each Class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-06-01_to_2023-06-01">Common stock, $0.00000002 par value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-06-01_to_2023-06-01">MEIP</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-06-01_to_2023-06-01" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-06-01_to_2023-06-01" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;8.01. Other Events. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;1, 2023, MEI Pharma, Inc. (the &#8220;Company&#8221; or &#8220;MEI&#8221;) issued a press release announcing that its Board of Directors (the &#8220;Board&#8221;) reviewed and rejected the unsolicited and <span style="white-space:nowrap">non-binding</span> proposal received on May&#160;23, 2023 from a group represented by Anson Advisors Inc. and Cable Car Capital LLC to acquire all outstanding shares of MEI for not less than $8.00 in cash per share, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of the Company&#8217;s clinical assets. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The press release is included herein as Exhibit 99.1 and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Important Information about the Merger and Where to Find It </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication relates to a proposed transaction between Infinity Pharmaceuticals, Inc. (&#8220;Infinity&#8221;) and MEI Pharma, Inc. (the &#8220;Company&#8221;). In connection with the proposed merger, the Company and Infinity plan to file with the SEC and mail or otherwise provide to their respective stockholders a joint proxy statement/prospectus regarding the proposed merger (as amended or supplemented from time to time, the &#8220;Joint Proxy Statement/Prospectus&#8221;). INVESTORS AND THE COMPANY&#8217;S AND INFINITY&#8217;S RESPECTIVE STOCKHOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY OTHER DOCUMENTS FILED BY EACH OF THE COMPANY AND INFINITY WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER AND THE PARTIES TO THE PROPOSED MERGER. Investors and stockholders will be able to obtain a free copy of the Joint Proxy Statement/Prospectus and other documents containing important information about the Company and Infinity, once such documents are filed with the SEC, from the SEC&#8217;s website at www.sec.gov. The Company and Infinity make available free of charge at www.meipharma.com and www.infi.com, respectively (in the &#8220;Investors&#8221; and &#8220;Investors/Media&#8221; sections, respectively), copies of materials they file with, or furnish to, the SEC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Participants in the Solicitation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company, Infinity and their respective directors, executive officers and certain employees and other persons may be deemed to be participants in the solicitation of proxies from the stockholders of the Company and Infinity in connection with the proposed merger. Securityholders may obtain information regarding the names, affiliations and interests of the Company&#8217;s directors and executive officers in the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended June&#160;30, 2022, which was filed with the SEC on September&#160;8, 2022, and its definitive proxy statement for the 2022 annual meeting of stockholders, which was filed with the SEC on October&#160;27, 2022. Securityholders may obtain information regarding the names, affiliations and interests of Infinity&#8217;s directors and executive officers in Infinity&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended December&#160;31, 2022, which was filed with the SEC on March&#160;28, 2023, and its definitive proxy statement for the 2022 annual meeting of stockholders, which was filed with the SEC on April&#160;25, 2022. Additional information regarding the interests of such individuals in the proposed merger will be included in the Joint Proxy Statement/Prospectus relating to the proposed merger when it is filed with the SEC. These documents (when available) may be obtained free of charge from the SEC&#8217;s website at www.sec.gov, the Company&#8217;s investor website at <span style="text-decoration:underline">https://www.meipharma.com/investors</span> and Infinity&#8217;s investor website at <span style="text-decoration:underline">https://investors.infi.com/</span>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Offer or Solicitation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section&#160;10 of the U.S. Securities Act of 1933, as amended. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cautionary Statement Regarding Forward-Looking Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements contained in this filing may be considered forward-looking statements within the meaning of the federal securities law. Such statements are based upon current plans, estimates and expectations of the management of the Company and Infinity that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;could,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; &#8220;contemplate,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221; &#8220;guidance,&#8221; &#8220;predict,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;pursue,&#8221; &#8220;likely,&#8221; and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including statements regarding: the expected timing of the closing of the proposed merger; the ability of the parties to complete the proposed merger considering the various closing conditions; the expected benefits of the proposed merger, including estimations of anticipated cost savings and cash runway; the competitive ability and position of the combined company; the potential, safety, efficacy, and regulatory and clinical progress of the combined company&#8217;s product candidates, including the anticipated timing for initiation of clinical trials and release of clinical trial data and the expectations surrounding potential regulatory submissions, approvals and timing thereof; the sufficiency of the combined company&#8217;s cash, cash equivalents and short-term investments to fund operations; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from the Company&#8217;s and Infinity&#8217;s plans, estimates or expectations could include, but are not limited to: (i)&#160;the risk that the proposed merger may not be completed in a timely manner or at all, which may adversely affect the Company&#8217;s and Infinity&#8217;s businesses and the price of their respective securities; (ii)&#160;uncertainties as to the timing of the consummation of the proposed merger and the potential failure to satisfy the conditions to the consummation of the proposed merger, including obtaining stockholder and regulatory approvals; (iii)&#160;the proposed merger may involve unexpected costs, liabilities or delays; (iv)&#160;the effect of the announcement, pendency or completion of the proposed merger on the ability of the Company or Infinity to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom the Company or Infinity does business, or on the Company&#8217;s or Infinity&#8217;s operating results and business generally; (v)&#160;the Company&#8217;s or Infinity&#8217;s respective businesses may suffer as a result of uncertainty surrounding the proposed merger and disruption of management&#8217;s attention due to the proposed merger; (vi)&#160;the outcome of any legal proceedings related to the proposed merger or otherwise, or the impact of the proposed merger thereupon; (vii)&#160;the Company or Infinity may be adversely affected by other economic, business, and/or competitive factors; (viii)&#160;the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement and the proposed merger; (ix)&#160;restrictions during the pendency of the proposed merger that may impact the Company&#8217;s or Infinity&#8217;s ability to pursue certain business opportunities or strategic transactions; (x)&#160;the risk that the Company or Infinity may be unable to obtain governmental and regulatory approvals required for the proposed merger, or that required governmental and regulatory approvals may delay the consummation of the proposed merger or result in the imposition of conditions that could reduce the anticipated benefits from the proposed merger or cause the parties to abandon the proposed merger; (xi)&#160;risks that the anticipated benefits of the proposed merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; (xii)&#160;the impact of legislative, regulatory, economic, competitive and technological changes; (xiii)&#160;risks relating to the value of the Company shares to be issued in the proposed merger; (xiv)&#160;the risk that integration of the proposed merger post-closing may not occur as anticipated or the combined company may not be able to achieve the benefits expected from the proposed merger, as well as the risk of potential delays, challenges and expenses associated with integrating the combined company&#8217;s existing businesses; (xv)&#160;exposure to inflation, currency rate and interest rate fluctuations, as well as fluctuations in the market price of the Company&#8217;s and Infinity&#8217;s traded securities; (xvi)&#160;the impact of the <span style="white-space:nowrap">COVID-19</span> pandemic on the Company&#8217;s and Infinity&#8217;s industry and individual companies, including on counterparties, the supply chain, the execution of clinical development programs, access to financing and the allocation of government resources; (xvii)&#160;final data from <span style="white-space:nowrap">pre-clinical</span> studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; (xviii)&#160;costs and delays in the development and/or U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval, or the failure to obtain such approval, of the combined company&#8217;s product candidates; (xix)&#160;uncertainties or differences in interpretation in clinical trial results; (xx)&#160;the combined company&#8217;s inability to maintain or enter into, and the risks resulting from dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any product candidates; and (xxi)&#160;the unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as the Company&#8217;s and Infinity&#8217;s response to any of the aforementioned factors. Additional factors that may affect the future results of the Company and Infinity are set forth in their respective filings with the United States Securities and Exchange Commission (the &#8220;SEC&#8221;), including each of the Company&#8217;s and Infinity&#8217;s most recently filed Annual Reports on Form <span style="white-space:nowrap">10-K,</span> subsequent Quarterly Reports on Form <span style="white-space:nowrap">10-Q,</span> Current Reports on Form <span style="white-space:nowrap">8-K</span> and other filings with the SEC, which are available on the SEC&#8217;s website at www.sec.gov. See in particular the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended June&#160;30, 2022 in Part I, Item 1A, &#8220;Risk Factors,&#8221; as updated by the Company&#8217;s Quarterly Reports on Form <span style="white-space:nowrap">10-Q</span> for the quarters ended September&#160;30, 2023, December&#160;31, 2022 and March&#160;31, 2023 in Part I, Item 1A, &#8220;Risk Factors&#8221; and Infinity&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended December&#160;31, 2022 in Part I, Item 1A, &#8220;Risk Factors,&#8221; as updated by Infinity&#8217;s Quarterly Reports on Form <span style="white-space:nowrap">10-Q</span> for the quarter ended March&#160;31, 2023, in Part I, Item 1A, &#8220;Risk Factors.&#8221; The risks and uncertainties described above and in the SEC filings cited above are not exclusive and further information concerning the Company and Infinity and their respective businesses, including factors that potentially could materially affect their respective businesses, financial conditions or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Any such forward-looking statements represent management&#8217;s reasonable estimates and beliefs as of the date of this press release. While the Company and Infinity may elect to update such forward-looking statements at some point in the future, they disclaim any obligation to do so, other than as may be required by law, even if subsequent events cause their views to change. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Form <span style="white-space:nowrap">8-K</span> contains hyperlinks to information that is not deemed to be incorporated by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;9.01. Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit&#160;No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d438169dex991.htm">Press Release of the Company dated June&#160;1, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">MEI PHARMA, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: June&#160;1, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel P. Gold</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Daniel P. Gold</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d438169dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g438169g71p62.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEI Pharma Board of Directors Rejects Unsolicited Proposal </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SAN DIEGO, June&nbsp;1, 2023 &#150; MEI Pharma, Inc. (NASDAQ: MEIP) (the &#147;Company&#148;) today announced that its Board of Directors (the
&#147;Board&#148;) reviewed and rejected the unsolicited and <FONT STYLE="white-space:nowrap">non-binding</FONT> proposal received on May&nbsp;23, 2023 from a group represented by Anson Advisors Inc. and Cable Car Capital LLC to acquire all
outstanding shares of MEI for not less than $8.00 in cash per share, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of the Company&#146;s clinical assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board, in consultation with the Company&#146;s financial and legal advisors, concluded that the unsolicited proposal significantly undervalues the
Company,&nbsp;is not superior to the proposed transaction with Infinity Pharmaceuticals, Inc. (&#147;Infinity&#148;)&nbsp;and does not provide a basis for discussions regarding an alternative transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The recommendation by the MEI Board to proceed with the pending Infinity transaction remains unchanged. MEI shareholders are advised that no action is
necessary at this time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stifel is serving as financial advisor to MEI Pharma and Morgan Lewis is serving as legal counsel. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About MEI Pharma </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEI Pharma, Inc. (Nasdaq: MEIP) is a
pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma&#146;s portfolio of drug candidates includes clinical stage candidates with differentiated mechanisms of action intended to address unmet medical needs and
deliver improved benefit to patients, either as standalone treatments or in combination with other therapeutic options. For more information, please visit&nbsp;<U>www.meipharma</U>.com. Follow us on Twitter @MEI_Pharma and on LinkedIn. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Information about the Merger and Where to Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication relates to a proposed transaction between Infinity Pharmaceuticals, Inc. (&#147;Infinity&#148;) and MEI Pharma, Inc. (the
&#147;Company&#148;). In connection with the proposed merger, the Company and Infinity plan to file with the SEC and mail or otherwise provide to their respective stockholders a joint proxy statement/prospectus regarding the proposed merger (as
amended or supplemented from time to time, the &#147;Joint Proxy Statement/Prospectus&#148;). INVESTORS AND THE COMPANY&#146;S AND INFINITY&#146;S RESPECTIVE STOCKHOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY WHEN IT
BECOMES AVAILABLE AND ANY OTHER DOCUMENTS FILED BY EACH OF THE COMPANY AND INFINITY WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER
AND THE PARTIES TO THE PROPOSED MERGER. Investors and stockholders will be able to obtain a free copy of the Joint Proxy Statement/Prospectus and other documents containing important information about the Company and Infinity, once such documents
are filed with the SEC, from the SEC&#146;s website at <U>www.sec.gov</U>. The Company and Infinity make available free of charge at <U>www.meipharma.com</U> and <U>www.infi.com</U>, respectively (in the &#147;Investors&#148; and
&#147;Investors/Media&#148; sections, respectively), copies of materials they file with, or furnish to, the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in the Solicitation
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company, Infinity and their respective directors, executive officers and certain employees and other persons may be deemed to be participants in
the solicitation of proxies from the stockholders of the Company and Infinity in connection with the proposed merger. Securityholders may obtain information regarding the names, affiliations and interests of the Company&#146;s directors and
executive officers in the Company&#146;s Annual Report <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;10-K&nbsp;for</FONT> the fiscal year ended June&nbsp;30, 2022, which was filed with the SEC on September&nbsp;8, 2022, and its definitive proxy
statement for the 2022 annual meeting of stockholders, which was filed with the SEC on October&nbsp;27, 2022. Securityholders may obtain information regarding the names, affiliations and interests of Infinity&#146;s directors and executive officers
in Infinity&#146;s Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the fiscal year ended December&nbsp;31, 2022, which was filed with the SEC on March&nbsp;28, 2023, and its definitive proxy statement for the 2022
annual meeting of stockholders, which was filed with the SEC on April&nbsp;25, 2022. Additional information regarding the interests of such individuals in the proposed merger will be included in the Joint Proxy Statement/Prospectus relating to the
proposed merger when it is filed with the SEC. These documents (when available) may be obtained free of charge from the SEC&#146;s website at <U>www.sec.gov</U>, the Company&#146;s investor website at <U>https://www.meipharma.com/investors</U> and
Infinity&#146;s investor website at <U>https://investors.infi.com/</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting
the requirements of Section&nbsp;10 of the U.S. Securities Act of 1933, as amended. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g438169g71p62.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Statement Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements contained in this filing may be considered forward-looking statements within the meaning of the federal securities law. Such statements are
based upon current plans, estimates and expectations of the management of the Company and Infinity that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of
forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as &#147;anticipate,&#148; &#147;expect,&#148; &#147;project,&#148; &#147;intend,&#148;
&#147;believe,&#148; &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;plan,&#148; &#147;could,&#148; &#147;continue,&#148; &#147;target,&#148; &#147;contemplate,&#148; &#147;estimate,&#148; &#147;forecast,&#148; &#147;guidance,&#148;
&#147;predict,&#148; &#147;possible,&#148; &#147;potential,&#148; &#147;pursue,&#148; &#147;likely,&#148; and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking
statements. All statements, other than historical facts, including statements regarding: the expected timing of the closing of the proposed merger; the ability of the parties to complete the proposed merger considering the various closing
conditions; the expected benefits of the proposed merger, including estimations of anticipated cost savings and cash runway; the competitive ability and position of the combined company; the potential, safety, efficacy, and regulatory and clinical
progress of the combined company&#146;s product candidates, including the anticipated timing for initiation of clinical trials and release of clinical trial data and the expectations surrounding potential regulatory submissions, approvals and timing
thereof; the sufficiency of the combined company&#146;s cash, cash equivalents and short-term investments to fund operations; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause
actual results to differ materially from the Company&#146;s and Infinity&#146;s plans, estimates or expectations could include, but are not limited to: (i)&nbsp;the risk that the proposed merger may not be completed in a timely manner or at all,
which may adversely affect the Company&#146;s and Infinity&#146;s businesses and the price of their respective securities; (ii)&nbsp;uncertainties as to the timing of the consummation of the proposed merger and the potential failure to satisfy the
conditions to the consummation of the proposed merger, including obtaining stockholder and regulatory approvals; (iii)&nbsp;the proposed merger may involve unexpected costs, liabilities or delays; (iv)&nbsp;the effect of the announcement, pendency
or completion of the proposed merger on the ability of the Company or Infinity to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom the Company or Infinity does business, or on the Company&#146;s
or Infinity&#146;s operating results and business generally; (v)&nbsp;the Company&#146;s or Infinity&#146;s respective businesses may suffer as a result of uncertainty surrounding the proposed merger and disruption of management&#146;s attention due
to the proposed merger; (vi)&nbsp;the outcome of any legal proceedings related to the proposed merger or otherwise, or the impact of the proposed merger thereupon; (vii)&nbsp;the Company or Infinity may be adversely affected by other economic,
business, and/or competitive factors; (viii)&nbsp;the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement and the proposed merger; (ix)&nbsp;restrictions during the pendency of the
proposed merger that may impact the Company&#146;s or Infinity&#146;s ability to pursue certain business opportunities or strategic transactions; (x)&nbsp;the risk that the Company or Infinity may be unable to obtain governmental and regulatory
approvals required for the proposed merger, or that required governmental and regulatory approvals may delay the consummation of the proposed merger or result in the imposition of conditions that could reduce the anticipated benefits from the
proposed merger or cause the parties to abandon the proposed merger; (xi)&nbsp;risks that the anticipated benefits of the proposed merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than
expected; (xii)&nbsp;the impact of legislative, regulatory, economic, competitive and technological changes; (xiii)&nbsp;risks relating to the value of the Company shares to be issued in the proposed merger; (xiv)&nbsp;the risk that integration of
the proposed merger post-closing may not occur as anticipated or the combined company may not be able to achieve the benefits expected from the proposed merger, as well as the risk of potential delays, challenges and expenses associated with
integrating the combined company&#146;s existing businesses; (xv)&nbsp;exposure to inflation, currency rate and interest rate fluctuations, as well as fluctuations in the market price of the Company&#146;s and Infinity&#146;s traded securities;
(xvi)&nbsp;the impact of <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> on the Company&#146;s and Infinity&#146;s industry and individual companies, including on counterparties, the supply chain, the execution of clinical
development programs, access to financing and the allocation of government resources; (xvii)&nbsp;final data <FONT STYLE="white-space:nowrap">from&nbsp;pre-clinical&nbsp;studies</FONT> and completed clinical trials may differ materially from
reported interim data from ongoing studies and trials; (xviii)&nbsp;costs and delays in the development and/or U.S. Food and Drug Administration (&#147;FDA&#148;) approval, or the failure to obtain such approval, of the combined company&#146;s
product candidates; (xix)&nbsp;uncertainties or differences in interpretation in clinical trial results; (xx)&nbsp;the combined company&#146;s inability to maintain or enter into, and the risks resulting from dependence upon, collaboration or
contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any product candidates; and (xxi)&nbsp;the unpredictability and severity of catastrophic events, including, but not limited
to, acts of terrorism or outbreak of war or hostilities, as well as the Company&#146;s and Infinity&#146;s response to any of the aforementioned factors. Additional factors that may affect the future results of the Company and Infinity are set forth
in their respective filings with the United States Securities and Exchange Commission (the &#147;SEC&#148;), including each of the Company&#146;s and Infinity&#146;s most recently filed Annual Reports on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K,&nbsp;subsequent</FONT> Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q,&nbsp;Current</FONT> Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;and</FONT> other filings
with the SEC, which are available on the SEC&#146;s website at <U>www.sec.gov</U>. See in particular the Company&#146;s Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the fiscal year ended June&nbsp;30, 2022 in Part
I, Item 1A, &#147;Risk Factors,&#148; as updated by the Company&#146;s Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;for</FONT> the quarters ended September&nbsp;30, 2023, December&nbsp;31, 2022 and March&nbsp;31, 2023 in
Part I, Item 1A, &#147;Risk Factors&#148; and Infinity&#146;s Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the fiscal year ended December&nbsp;31, 2022 in Part I, Item 1A, &#147;Risk Factors,&#148; as updated by
Infinity&#146;s Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;for</FONT> the quarter ended March&nbsp;31, 2023, in Part I, Item 1A, &#147;Risk Factors.&#148; The risks and uncertainties described above and in the SEC
filings cited above are not exclusive and further information concerning the Company and Infinity and their respective businesses, including factors that potentially could materially affect their respective businesses, financial conditions or
operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Any such forward-looking
statements represent management&#146;s reasonable estimates and beliefs as of the date of this press release. While the Company and Infinity may elect to update such forward-looking statements at some point in the future, they disclaim any
obligation to do so, other than as may be required by law, even if subsequent events cause their views to change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David A. Walsey </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">858-369-7104</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>investor@meipharma.com </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joele Frank, Wilkinson Brimmer Katcher </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dan Katcher / Aaron
Palash </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-355-4449</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">MEIP-jf@joelefrank.com</FONT> </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>meip-20230601.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 6/1/2023 2:12:13 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:meip="http://www.meipharma.com/20230601"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.meipharma.com/20230601"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="meip-20230601_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="meip-20230601_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>meip-20230601_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 6/1/2023 2:12:13 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>meip-20230601_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 6/1/2023 2:12:13 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="meip-20230601.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g438169g71p62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g438169g71p62.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @,# @(# @(" P0# P,#! 0$ @,$! 0$! ,$! ,! @(" @(" @(" @,"
M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# __$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MSS#YI_:>6T\JQ^4X^K@*U&EB/K-/FITJ%7GC5]G2NFJR5N32Q>Q^+W_!3?\
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M_L:/BE_ZJ7Q+0!]%T ?/OCG_ ).)_9__ .Q2^.?_ *3_  XH ^@J / O$/\
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M,TVRBTVSU*6\^%=WXECM8(DB@#^(KSX4RWL\R1*JB:65Y#C+.6))-OD&WR/
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8IZZ[J-O&^GO:*T$B1R(XB0J;?(-OD?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140072066460752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001262104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  01,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MEI Pharma, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">51-0407811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11455 El Camino Real<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">369-7100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, $0.00000002 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MEIP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d438169d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="meip-20230601.xsd" xlink:type="simple"/>
    <context id="duration_2023-06-01_to_2023-06-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001262104</identifier>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-01</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-06-01_to_2023-06-01">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-06-01_to_2023-06-01"
      id="Hidden_dei_EntityCentralIndexKey">0001262104</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-06-01_to_2023-06-01">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-06-01_to_2023-06-01">2023-06-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-06-01_to_2023-06-01">MEI Pharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-06-01_to_2023-06-01">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-06-01_to_2023-06-01">000-50484</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-06-01_to_2023-06-01">51-0407811</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-06-01_to_2023-06-01">11455 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-06-01_to_2023-06-01">Suite 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-06-01_to_2023-06-01">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-06-01_to_2023-06-01">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-06-01_to_2023-06-01">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-06-01_to_2023-06-01">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-06-01_to_2023-06-01">369-7100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-06-01_to_2023-06-01">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-06-01_to_2023-06-01">true</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-06-01_to_2023-06-01">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-06-01_to_2023-06-01">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-06-01_to_2023-06-01">Common stock, $0.00000002 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-06-01_to_2023-06-01">MEIP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-06-01_to_2023-06-01">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-06-01_to_2023-06-01">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  90L%6'#AEZC\!   \ @  #P
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M=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ &4+!5B0>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( !E"P59ED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    "  90L%6Y-^5Q.X    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  90L%6
MF5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( !E"P589$/3>800  "D1   8              "
M@0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  90L%6
MGZ ;\+$"  #B#   #0              @ &D#   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( !E"P5:7BKL<P    !,"   +              "  8 /  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( !E"P58<.&7J/P$  #P"   /
M      "  6D0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  90L%6)!Z;
MHJT   #X 0  &@              @ '5$0  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    "  90L%699!YDAD!  #/ P  $P
M    @ &Z$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   $
%%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d438169d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d438169d8k.htm">d438169d8k.htm</File>
    <File>d438169dex991.htm</File>
    <File>meip-20230601.xsd</File>
    <File>meip-20230601_lab.xml</File>
    <File>meip-20230601_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d438169d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d438169d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "meip-20230601_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "meip-20230601_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "meip-20230601.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "meip",
   "nsuri": "http://www.meipharma.com/20230601",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d438169d8k.htm",
      "contextRef": "duration_2023-06-01_to_2023-06-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d438169d8k.htm",
      "contextRef": "duration_2023-06-01_to_2023-06-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.meipharma.com//20230601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-23-158451-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-158451-xbrl.zip
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M)9#G%O/,TYNM6-S$=1J1U;%?W0[*&'L]5/[\[6M?7C$=SP/Q9LN7>A;P.;*
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M]@?T3 "_S66@P#[.I9,AQN=1CEQQD"BH[J7^;"9(0NOPT'JICT=RR..81.3
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M'P.DPI'">;8:^S3!XOV5%$'0#FP)AN&\M<O&*@<,I\ZH<M,2L#$PR",RF>F
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M. D#*H,_H O1?)9F(DES$2ECB'2)^*^7.T^?"IV(0)J%6*K,[NB)9508H!>
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M849R<J\RV](P&K9 4IUT2IV'  [:6&UOI\RD*U4GD_;.BKR JCB1LJ5L;E6
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M=] Q33;Y%1]Z D05>5(B;!M.N/J"AM>NU,J5S1,5^<XJQ^.NL@1"+_3232[
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M._Q1??-UPA7MIS.9"#](=NM%^A1Q4>Q,39ST#$F#W89TW*D(=K1\$10Z:O.
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MOE4KAB%XAA^,D3@-0V5 YE^N*"/#9N-@%.AT%.HL\0.![B-0*8J+?Z[_IM@
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MB5O^!E!+ 0(4 Q0    ( !E"P5;01\+,:AX  %J8   .              "
M 0    !D-#,X,38Y9#AK+FAT;5!+ 0(4 Q0    ( !E"P5:"U3P:;!8  +)'
M   1              "  98>  !D-#,X,38Y9&5X.3DQ+FAT;5!+ 0(4 Q0
M   ( !E"P5889NW8.P,  $X+   1              "  3$U  !M96EP+3(P
M,C,P-C Q+GAS9%!+ 0(4 Q0    ( !E"P58+$3]Q> 8  +A&   5
M      "  9LX  !M96EP+3(P,C,P-C Q7VQA8BYX;6Q02P$"% ,4    "  9
M0L%60/;_U[\$  ! +   %0              @ %&/P  ;65I<"TR,#(S,#8P
?,5]P<F4N>&UL4$L%!@     %  4 0 $  #A$      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
